Literature DB >> 33190426

Effects of variable domain orientation on anti-HER2 single-chain variable fragment antibody expressed in the Escherichia coli cytoplasm.

İlkay Koçer1,2, Emily C Cox3, Matthew P DeLisa2,3, Eda Çelik1,4.   

Abstract

Single-chain variable fragment (scFv) antibodies have great potential for a range of applications including as diagnostic and therapeutic agents. However, production of scFvs is challenging because proper folding and activity depend on the formation of two intrachain disulfide bonds that do not readily form in the cytoplasm of living cells. Functional expression in bacteria therefore involves targeting to the more oxidizing periplasm, but yields in this compartment can be limiting due to secretion bottlenecks and the relatively small volume compared to the cytoplasm. In the present study, we evaluated an anti-HER2 scFv, which is specific for human epidermal growth receptor 2 (HER2) overexpressed in breast cancer, for functional expression in the cytoplasm of Escherichia coli strains BL21(DE3) and SHuffle T7 Express, the latter of which is genetically engineered for cytoplasmic disulfide bond formation. Specifically, we observed much greater solubility and binding activity with SHuffle T7 Express cells, which likely resulted from the more oxidative cytoplasm in this strain background. We also found that SHuffle T7 Express cells were capable of supporting high-level soluble production of anti-HER2 scFvs with intact disulfide bonds independent of variable domain orientation, providing further evidence that SHuffle T7 Express is a promising host for laboratory and preparative expression of functional scFv antibodies.
© 2020 American Institute of Chemical Engineers.

Entities:  

Keywords:  VL/VH orientation; anti-HER2; cytoplasmic expression; scFv

Mesh:

Substances:

Year:  2020        PMID: 33190426      PMCID: PMC8842847          DOI: 10.1002/btpr.3102

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  49 in total

Review 1.  Enhancement of soluble protein expression through the use of fusion tags.

Authors:  Dominic Esposito; Deb K Chatterjee
Journal:  Curr Opin Biotechnol       Date:  2006-06-15       Impact factor: 9.740

Review 2.  Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.

Authors:  Nina E Weisser; J Christopher Hall
Journal:  Biotechnol Adv       Date:  2009-04-15       Impact factor: 14.227

3.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

4.  Anti-HER2 scFv Expression in Escherichia coli SHuffle®T7 Express Cells: Effects on Solubility and Biological Activity.

Authors:  Maryam Ahmadzadeh; Farzaneh Farshdari; Leila Nematollahi; Mahdi Behdani; Elham Mohit
Journal:  Mol Biotechnol       Date:  2020-01       Impact factor: 2.695

Review 5.  Fusion protein linkers: property, design and functionality.

Authors:  Xiaoying Chen; Jennica L Zaro; Wei-Chiang Shen
Journal:  Adv Drug Deliv Rev       Date:  2012-09-29       Impact factor: 15.470

Review 6.  HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches.

Authors:  Miriam Colombo; Fabio Corsi; Diego Foschi; Elisa Mazzantini; Serena Mazzucchelli; Carlo Morasso; Emanuela Occhipinti; Laura Polito; Davide Prosperi; Silvia Ronchi; Paolo Verderio
Journal:  Pharmacol Res       Date:  2010-02-01       Impact factor: 7.658

7.  Development of humanized scFv antibody fragment(s) that targets and blocks specific HLA alleles linked to myasthenia gravis.

Authors:  B Vijayalakshmi Ayyar; M Zouhair Atassi
Journal:  Appl Microbiol Biotechnol       Date:  2017-10-15       Impact factor: 4.813

8.  Improved biological activity of a single chain antibody fragment against human epidermal growth factor receptor 2 (HER2) expressed in the periplasm of Escherichia coli.

Authors:  Vajihe Akbari; Hamid Mir Mohammad Sadeghi; Abbas Jafarian-Dehkordi; Daryoush Abedi; C Perry Chou
Journal:  Protein Expr Purif       Date:  2015-07-10       Impact factor: 1.650

9.  The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi.

Authors:  Vivi Joosten; Christien Lokman; Cees AMJJ Van Den Hondel; Peter J Punt
Journal:  Microb Cell Fact       Date:  2003-01-30       Impact factor: 5.328

10.  Isolation and characterization of camelid single-domain antibodies against HER2.

Authors:  Greg Hussack; Shalini Raphael; Michael J Lowden; Kevin A Henry
Journal:  BMC Res Notes       Date:  2018-12-05
View more
  1 in total

1.  Expression, purification and characterisation of a human anti-CDK4 single-chain variable fragment antibody.

Authors:  Jialiang Zhao; Jingjing Xu; Tianbin Yang; Xinze Yu; Cheng Cheng; Tong Zhang; Ze Ren; Na Li; Fang Yang; Guiying Li
Journal:  BMC Biotechnol       Date:  2021-12-20       Impact factor: 2.563

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.